Key Insights

Highlights

Treatment Research

7 treatments under study, led by Imatinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04877522Phase 4Recruiting

Asciminib Roll-over Study

Showing all 1 trials

Research Network

Common Treatments

  • Imatinib1
  • Bosutinib1
  • Asciminib Hydrochloride1
  • Nilotinib1
  • Asciminib Single Agent1

Active Sponsors

  • Novartis Pharma AG1
  • Novartis Pharmaceuticals1

Related Conditions

  • Leukemia Myelogenous Chronic Bcrabl Positive1
  • Chronic Myelogenous Leukemia1

Activity Timeline